Besides, there has been limited success (almost none) in drug development and repurposing efforts for its effective treatment. In part, this lack of success arises out of the fact that the drug design process targeting AD has been flanked by a reductionist "1-target --1-drug" model. So far, this approach has not provided an effective therapeutic alternative due to the multifactorial nature of this pathology 3 . Therefore, there's a need to shift the focus of current AD drug discovery research towards designing a better therapeutic solution for simultaneously targeting the multiple pathological mechanisms responsible for AD's onset and aggravation (some of which are likewise prevalent in other neurodegenerative diseases).